1. A novel TREX1 inhibitor, VB-85680, upregulates cellular interferon responses.
- Author
-
Flowers, Stephen, Petronella, Brenda A., McQueney, Michael S., Fanelli, Barbara, Eisenberg, Warren, Uveges, Albert, Roden, Allison L., Salowe, Scott, Bommireddy, Venu, Letourneau, Jeffrey J., Huang, Chia-Yu, and Beasley, James R.
- Subjects
- *
SECOND messengers (Biochemistry) , *T cells , *GENETIC regulation , *CELL lines , *INTERFERONS - Abstract
Activation of the cGAS-STING pathway plays a key role in the innate immune response to cancer through Type-1 Interferon (IFN) production and T cell priming. Accumulation of cytosolic double-stranded DNA (dsDNA) within tumor cells and dying cells is recognized by the DNA sensor cyclic GMP-AMP synthase (cGAS) to create the secondary messenger cGAMP, which in turn activates STING (STimulator of INterferon Genes), resulting in the subsequent expression of IFN-related genes. This process is regulated by Three-prime Repair EXonuclease 1 (TREX1), a 3' → 5' exonuclease that degrades cytosolic dsDNA, thereby dampening activation of the cGAS-STING pathway, which in turn diminishes immunostimulatory IFN secretion. Here, we characterize the activity of VB-85680, a potent small-molecule inhibitor of TREX1. We first demonstrate that VB-85680 inhibits TREX1 exonuclease activity in vitro in lysates from both human and mouse cell lines. We then show that treatment of intact cells with VB-85680 results in activation of downstream STING signaling, and activation of IFN-stimulated genes (ISGs). THP1-Dual™ cells cultured under low-serum conditions exhibited an enhanced ISG response when treated with VB-85680 in combination with exogenous DNA. Collectively, these findings suggest the potential of a TREX1 exonuclease inhibitor to work in combination with agents that generate cytosolic DNA to enhance the acquisition of the anti-tumor immunity widely associated with STING pathway activation. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF